Skip to main content
Premium Trial:

Request an Annual Quote

New mRNA Vaccine Interest

The French drugmaker Sanofi plans to invest €400 million (US $477 million) a year into mRNA vaccine research, according to the Wall Street Journal.

It adds that the mRNA vaccines developed COVID-19 pandemic illustrated to the company the value of the approach. "During the COVID-19 pandemic, mRNA technologies demonstrated potential to deliver new vaccines faster than ever before," Jean-François Toussaint, the head of research and development at Sanofi Pasteur, says in a statement.

The Journal notes that the mRNA vaccine field had been the purview of small companies – like Moderna and BioNTech, which developed SARS-CoV-2 vaccine – as their development requires different tools than traditional vaccine work and had not, but that now larger pharmaceutical firms like Sanofi, but also Pfizer and GlaxoSmithKline are expanding into the field.

Sanofi says it plans to establish an mRNA vaccine research center with 400 employees and that the center will help accelerate the development of mRNA vaccines develop through its collaboration with Translate Bio.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.